Basic Information
ID DDInter359 and DDInter1603
Interaction Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity.
Management Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs. These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.
References [1] "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals (2002): [2] "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals (2001): [3] "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc (2022): [4] "Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation (2001): [5] "Product Information. Chloroquine Phosphate (chloroquine)." West Ward Pharmaceutical Corporation (2005): [6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 [7] Cerner Multum, Inc. "Australian Product Information." O 0 [8] "Product Information. Sabril (vigabatrin)." Lundbeck Inc (2009): [9] "Product Information. Deferoxamine Mesylate (deferoxamine)." Hospira Inc (2015): [10] Cerner Multum, Inc "ANVISA Bul鐠嬶箶io Eletr娑斿潱ico." O 0 (2015): [11] "Product Information. Cotellic (cobimetinib)." Genentech (2015): [12] "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories (2017): [13] "Product Information. Thioridazine Hydrochloride (thioridazine)." Mylan Institutional (formerly UDL Laboratories) (2019): [14] "Product Information. Koselugo (selumetinib)." Astra-Zeneca Pharmaceuticals (2020): [15] "Product Information. Truseltiq (infigratinib)." QED Therapeutics Inc (2021):
Alternative for Chloroquine P01B
Proguanil Halofantrine Primaquine Atovaquone Artesunate Pyrimethamine
Quinine Artemether Mefloquine Lumefantrine Tafenoquine Sulfadoxine
Alternative for Risdiplam M09A
Collagenase clostridium histolyticum Hyaluronic acid Onasemnogene abeparvovec
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.